XBIT
MaterialsXBiotech Inc
Live · NASDAQ · May 9, Close
What's Moving XBIT Today?
No stock-specific AI insight has been generated for XBIT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
XBIT News
9 articles- XBiotech: Q4 Earnings SnapshotYahoo Finance·Mar 13, 2026
- 3 Promising Penny Stocks With Market Caps Over $30MYahoo Finance·Dec 19, 2025
- November 2025's Promising Penny Stocks To WatchYahoo Finance·Nov 12, 2025
- XBiotech: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insidersYahoo Finance·Aug 28, 2025
- XBiotech: Q2 Earnings SnapshotYahoo Finance·Aug 13, 2025
- 3 Promising Penny Stocks With Market Caps Above $90MYahoo Finance·Jul 2, 2025
- Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn SituationYahoo Finance·May 16, 2025
- XBiotech: Q1 Earnings SnapshotYahoo Finance·May 14, 2025
All 9 articles loaded
Price Data
Fundamentals
Trading
About XBiotech Inc
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.